In Silico Evaluation of Molecular Docking, Molecular Dynamic, and ADME Study of New Nabumetone Schiff Base Derivatives (1,3,4-oxadiazole or 1,3,4-thiadiazole ring) Promising Antiproliferation Action Against Lung Cancer

Year 2024, Volume: 8 Issue: 4, 114 - 126, 02.12.2024

Ahmed Haloob , Monther Faisal , Ayad Mr Raauf

https://doi.org/10.33435/tcandtc.1494129

Abstract

A total of eight novel Nabumetone Schiff Base Derivatives with 1,3,4-oxadiazole or 1,3,4-thiadiazole rings have been proposed to evaluate their potential effectiveness against the epidermal growth factor receptor (EGFR). Molecular docking was conducted with the crystalline structure of EGFR (code: 4HJO), wherein the eight compounds of Nabumetone Schiff Base Derivatives with 1,3,4-oxadiazole or 1,3,4-thiadiazole ring derivatives docked to determine their binding affinity to the target binding site. Using GOLD software (CCDC) version 5.43, computer predictions were made, and the compounds were designed using ChemDraw version 22.2 (professional version). Subsequently, their selectivity with EGFR was assessed, with erlotinib selected as a control for comparison. In silico ADME studies were conducted, revealing the significant potential for binding, and drug-likeness was assessed using the Swiss ADME website. Additionally, Molecular Dynamic simulations of compound N3 complexes with EGFR were performed using Schrodinger Suite 2023 software for 50 ns, estimating RMSD, RMSF, Ligand-Protein Contacts, and Ligand Torsion Profile results. Result Showing the best binding energy within receptor pocket with a promising activity against EGFR protein receptor. The highest PLP fitness levels were found in compounds N1, N2, and N3 for lung cancer cell protein (89.1, 89.02, and 87.95, respectively, average value), All compounds were found to adhere to Lipinski's rule of five, with high absorption from the gastrointestinal tract (except N4), and none of the proposed compounds were able to pass through the blood-brain barrier. Molecular dynamic result, Mean Protein RMSD 1.8 Å, ligand RMSD 1.6 Å, and RMSF reveals that the protein amino acids interacting with the ligand remain within a distance of less than 1 Å. In conclusion, these findings offer a promising direction for the development of effective treatments for lung cancer

Keywords

Nabumetone Schiff Base, oxadiazole, thiadiazole, 4HJO, Molecular Dynamic, Molecular Docking, EGFR protein receptor

References

• [1] Bade BC, Cruz CSD. Lung cancer 2020: epidemiology, etiology, and prevention. Clinics in Chest Medicine 41 (2020) 1-24.
• [2] Cruz CSD, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clinics in Chest Medicine 32 (2011) 605-644.
• [3] Hasan HA, Ali KF, Mehdi WA. Synthesis, characterization, docking study and biological activities of new 3-aminorhodanine derivatives. Al Mustansiriyah Journal of Pharmaceutical Sciences 24 (2024) 299-310.
• [4] Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cellular and Molecular Life Sciences 65 (2008) 1566-1584.
• [5] Khozin S, Blumenthal GM, Jiang X, He K, Boyd K, Murgo A, et al. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. The Oncologist 19 (2014) 774-779.
• [6] Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clinical Biochemistry 37 (2004) 618-635.
• [7] Stein RA, Staros JV. Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis. BMC Evolutionary Biology 6 (2006) 79.
• [8] Agarwal SM, Nandekar P, Saini R. Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADME, machine learning, molecular docking and a dynamics approach. RSC Advances 12 (2022) 16779-16789.
• [9] Ismail R, Ismail N, Abuserii S, Abou El Ella DA. Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents. Future Journal of Pharmaceutical Sciences 2 (2016).
• [10] Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 16 (2012) 15-31.
• [11] Jedhe GS, Paul D, Gonnade RG, Santra MK, Hamel E, Nguyen TL, Sanjayan GJ. Correlation of hydrogen-bonding propensity and anticancer profile of tetrazole-tethered combretastatin analogues. Bioorganic & Medicinal Chemistry Letters 23 (2013) 4680-4684.
• [12] Yadav IS, Singh H, Khan MI, Chaudhury A, Raghava GP, Agarwal SM. EGFRIndb: epidermal growth factor receptor inhibitor database. Anti-Cancer Agents in Medicinal Chemistry 14 (2014) 928-935.
• [13] Ahmed M, Sadek MM, Abouzid KA, Wang F. In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2. Journal of Molecular Graphics and Modelling 44 (2013) 220-231.
• [14] Alonso H, Bliznyuk AA, Gready JE. Combining docking and molecular dynamic simulations in drug design. Medicinal Research Reviews 26 (2006) 531-568.
• [15] Zappavigna S, Cossu AM, Grimaldi A, Bocchetti M, Ferraro GA, Nicoletti GF, Filosa R, Caraglia M. Anti-inflammatory drugs as anticancer agents. International Journal of Molecular Sciences 21 (2020) 2605.
• [16] Roy HK, Karoski WJ, Ratashak A, Smyrk TC. Chemoprevention of intestinal tumorigenesis by nabumetone: induction of apoptosis and Bcl-2 downregulation. British Journal of Cancer 84 (2001) 1412-1416.
• [17] Kumar A, Singh AK, Singh H, Vijayan V, Kumar D, Naik J, et al. Nitrogen containing heterocycles as anticancer agents: a medicinal chemistry perspective. Pharmaceuticals 16 (2023) 299.
• [18] Kerru N, Gummidi L, Maddila S, Gangu KK, Jonnalagadda SB. A review on recent advances in nitrogen-containing molecules and their biological applications. Molecules 25 (2020) 1909.
• [19] Janowska S, Paneth A, Wujec M. Cytotoxic properties of 1,3,4-thiadiazole derivatives—A review. Molecules 25 (2020) 4309.
• [20] Glomb T, Szymankiewicz K, Świątek P. Anti-cancer activity of derivatives of 1,3,4-oxadiazole. Molecules 23 (2018) 3361.
• [21] Fu Y, Zhao J, Chen Z. Insights into the molecular mechanisms of protein-ligand interactions by molecular docking and molecular dynamics simulation: a case of oligopeptide binding protein. Computational and Mathematical Methods in Medicine 2018 (2018) 3502514
• [22] Patil R, Das S, Stanley A, Yadav L, Sudhakar A, Varma AK. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLOS ONE 5 (2010) e12029.
• [23] Chen X, Li H, Tian L, Li Q, Luo J, Zhang Y. Analysis of the physicochemical properties of acaricides based on Lipinski’s rule of five. Journal of Computational Biology 27 (2020) 1397-1406.